Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Thursday announced the full year financial results for 2025 and provided updates on corporate activities and drug development.
Operational Highlights
The company highlighted certain pharmaceutical developments, including the preclinical advancement of its GABAB PAM candidate in treating chronic cough, and the preparation for dipraglurant clinical studies in post-stroke recovery. The future development of the mGlu2PAM program was evaluated, and the company regained rights to the Phase 2 mGlu2 PAM asset ADX71149.
Additionally, Addex and partner company Individor advanced a GABAB PAM substance use disorders program through investigational new drug (IND) enabling studies. The company invested in Stalicla SA, a spin-out from Neurosterix, and gained a 20% equity interest in Neurosterix following a sale of a part of Addex's business.
2025 Financial Results
In 2025, Addex recorded a total income of CHF 0.17 million, while the same in 2024 was CHF 0.41 million.
Research and Development (R&D) expenses for the year came to CHF 0.67 million, approximately CHF 0.2 million less than CHF 0.85 million R&D expenses in 2024.
General and Administrative (G&A) expenses remained stable at CHF 2.31 million across 2024 and 2025.
The company reported a loss of CHF 6.73 million, or CHF 0.06 per share, in 2025, while in 2024, it showed a profit of CHF 7.06 million, or CHF 0.07 per share.
As of December 31, 2025, cash and cash equivalents of the company amounted to CHF 1.64 million.
ADXN closed Wednesday at $7.00, up 3.86%. In the pre-market, the stock is trading at $6.93, down 1.00%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.